Skip to main content
OpenTrials
Completed

NCT Number: NCT07746986

DECIPHERING AND TARGETING VEXAS

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome (1/4,000 males aged >50) is a paradigmatic age-onset acquired, severe, autoinflammatory hematological disease due to clonal dominance of hematopoietic cells bearing a somatic mutation in the UBA1 (ubiquitin-activating enzyme 1) gene. VEXAS presents with treatment-refractory systemic myeloid-driven inflammatory manifestations and hematologic abnormalities, hence the poor prognosis. Current available therapies are poorly effective and burdened by debilitating side effects. VEXAS mutations inactivate cytoplasmic UBA1-driven ubiquitination, impairing protein clearance and triggering stress responses. By innovative base-editing (patent PCTIB2024060412), the investigators generated new in vitro and in vivo models that, along with comprehensive phenotyping of VEXAS patients, disclosed progressive inflammatory poisoning of healthy hematopoiesis and resilience to inflammation of UBA1-mutant hematopoietic stem/progenitor cells (HSPC) as key mechanisms of inflammation and clonal dominance.

Deciphering these mechanisms might reveal predictive markers, actionable targets, and inform drug repurposing or novel therapies. The investigators hypothesize that cell-intrinsic and -extrinsic mechanisms triggered by altered UBA1 function are targetable drivers linking inflammation and clonal dominance.

The research plan is designed to investigate, both in vitro and in BM and peripheral hematopoietic cells from VEXAS patients, the key pathogenic mechanisms sustaining inflammation and clonal dominance in VEXAS syndrome. Patients with VEXAS syndrome, defined by the presence of pathogenic mutations in the UBA1 gene identified in hematopoietic cells isolated from the peripheral blood of individuals with systemic autoinflammatory disease, will be included in the study population. The study will also enroll healthy control subjects, matched as closely as possible for age and sex, with no history of inflammatory or hematologic disorders. The dissection of mechanisms underlying the interplay between inflammation and clonal dominance will be fundamental to identify novel therapeutic strategies against disease progression that would enable the treatment of VEXAS patients at early disease stages, improving prognosis and life expectancy. Moreover, establishing robust genotype-to-phenotype correlations in patients may inform the design of personalized therapeutic options. The obtained results may inform the design of new therapeutic strategies against this cureless disease.

Overall, in this observational monocentric study the investigators will use retrospective samples collected from 2020 to 2026 to conduct cytokine profiling and comprehensive omics-based characterization (transcriptomics, proteomics, metabolomics) on peripheral blood-derived monocytes/neutrophils and bone marrow (BM) hematopoietic cells.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

VEXAS Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms VEXAS syndrome

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

IRCCS Ospedale San Raffaele

Milan, MI, 20129, Italy

About this study

Primary Objective. To validate, in patients affected by VEXAS syndrome, the pathogenic mechanisms associated with UBA1-mutant hematopoietic cells, with particular focus on their role in promoting systemic inflammation and clonal dominance.

Primary Endpoint. Differences in the production of pro-inflammatory cytokines/chemokines by monocytes isolated from VEXAS patients compared with healthy controls, assessed by multiplex immunoassay. The primary endpoint will be assessed on blood samples collected retrospectively.

Secondary Objectives.

  • To evaluate the role of autophagy and unfolded protein response (UPR) pathways in regulating the inflammatory response in VEXAS monocytes.
  • To characterize multi-omic profiles (transcriptomics, proteomics, metabolomics) of hematopoietic cells from BM and peripheral blood.
  • To compare molecular profiles between UBA1-mutant cells and cells from healthy donors.
  • To investigate genotype-phenotype correlations associated with different UBA1 mutations.
  • To integrate ex vivo findings with data generated from in vitro models.

Secondary Endpoints.

  • Changes in cytokine production following ex vivo modulation of autophagy and UPR pathways.
  • Changes in transcriptomic profiles (RNA-seq) following ex vivo modulation of autophagy and UPR pathways.
  • Proteomic and metabolomic profiles of hematopoietic cells from bone marrow and peripheral blood.
  • Quantitative and qualitative differences across UBA1 mutation subgroups.
  • Correlations between molecular data and available clinical features. Secondary endpoints will be assessed on samples collected retrospectively.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with VEXAS syndrome:
  • Diagnosed with VEXAS syndrome by identification of pathogenic mutations in the UBA1 gene in hematopoietic cells isolated from peripheral blood in the presence of systemic autoinflammatory disease.
  • Age >18.
  • BM and peripheral blood samples were collected between 2020 and 2026.
  • Healthy donors:
  • In good general health as evidenced by medical history, with no history of inflammatory or hematologic disorders. BM samples derive from subjetcs undergoing hip replacement.
  • Matched as closely as possible with VEXAS patients by age and sex.
  • Age >18.
  • BM and peripheral blood samples were collected between 2020 and 2026.

Exclusion criteria

  • Subjects not included in the previous criteria

Treatment and study plan

Primary outcomes

  1. Inflammatory cytokine production

    Time frame: Through study completion, an average of 1 year

    Differences in the production of pro-inflammatory cytokines/chemokines by monocytes isolated from VEXAS patients compared with healthy controls, assessed by multiplex immunoassay.

Secondary outcomes

  1. Effect of autophagy and UPR modulation on inflammatory cytokine production

    Time frame: Through study completion, an average of 1 year

    • Changes in cytokine production following ex vivo modulation of autophagy and UPR pathways in cells from VEXAS patients compared with healthy controls.

  2. Changes in expression profiles following ex vivo modulation of autophagy and UPR pathways.

    Time frame: Through study completion, an average of 1 year

    • Transcriptomic, proteomic, ubiquitomic, and metabolomic profiles of hematopoietic cells from bone marrow and peripheral blood from VEXAS patients compared with healthy controls upon ex vivo modulation of autophagy and UPR pathways.

  3. Quantitative and qualitative differences across UBA1 mutation subgroups.

    Time frame: Through study completion, an average of 1 year

    • Correlations between molecular data and available clinical features.

Sponsors and collaborators

Lead sponsor

IRCCS San Raffaele

Other

Registry information

Official study title

Devising Targeted Therapies Against VEXAS Syndrome by Untangling the Vicious Interplay of Inflammation and Clonal Dominance

Acronym: DTV

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Aug 5, 2026
Registry last updated
Aug 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.